Severe lung injury induced by <scp>CD38</scp> monoclonal antibody Daratumumab and bortezomib‐containing regimen in a patient with preexisting interstitial lung disease: a case report and literature review-Reference-Cited by-同舟云学术

Severe lung injury induced by CD38 monoclonal antibody Daratumumab and bortezomib‐containing regimen in a patient with preexisting interstitial lung disease: a case report and literature review

Published:2022-12 Issue:12 Volume:47 Page:2387-2392
ISSN:0269-4727
Container-title:Journal of Clinical Pharmacy and Therapeutics
language:en
Short-container-title:Clinical Pharmacy Therapeu

Author:

Chen Meng¹²^ORCID,Zhao Lei¹²,Yao Fang¹²,Yang Xiang Dong¹²

Affiliation:

1. Department of Hematology First Teaching Hospital of Tianjin University of Traditional Chinese Medicine Tianjin China

2. National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion Tianjin China

Funder

National Natural Science Foundation of China

Publisher

Hindawi Limited

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcpt.13819

Reference20 articles.

1. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

2. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

3. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

4. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

5. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS);American Thoracic Society;Am J Respir Crit Care Med,2000

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bortezomib/daratumumab;Reactions Weekly;2023-01-14